1. Scrip
  2. >>Therapy Areas

Charting The Slow-Growing Psoriatic Arthritis Market

 
• By Emily Hayes

Market Snapshot: Despite the availability of anti-TNF biosimilars, the global market for drugs for psoriatic arthritis will grow to $4.1bn in 2025 due to the entry of new branded drugs at high prices in the US, according to a new Datamonitor Healthcare forecast report.

snail showing slow growth

The US FDA's recent approvals of Pfizer Inc.'s JAK inhibitor Xeljanz, Eli Lilly & Co.'s IL-17A inhibitor Taltz and Johnson & Johnson's infused anti-TNF Simponi Aria for psoriatic arthritis brings three more products into a crowded space already dominated by mainstay TNF blockers, which are beginning to face biosimilars competition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.